{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05858619",
            "orgStudyIdInfo": {
                "id": "21-35748"
            },
            "organization": {
                "fullName": "University of California, San Francisco",
                "class": "OTHER"
            },
            "briefTitle": "Molecular Signatures of Cutaneous Dupilumab Response",
            "officialTitle": "Molecular Signatures of Cutaneous Dupilumab Response",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "molecular-signatures-of-cutaneous-dupilumab-response"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-04",
            "studyFirstSubmitQcDate": "2023-05-04",
            "studyFirstPostDateStruct": {
                "date": "2023-05-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of California, San Francisco",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.",
            "detailedDescription": "This is a one-arm, open-label study to examine the effect of dupilumab. Dupilumab is a FDA-approved medication for the treatment of atopic dermatitis. This study will examine how dupilumab affects immune cells within atopic dermatitis skin lesions. Fifteen subjects with moderate to severe atopic dermatitis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict dupilumab treatment response."
        },
        "conditionsModule": {
            "conditions": [
                "Atopic Dermatitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "dupilumab treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Treatment with IL4RA inhibitor",
                    "interventionNames": [
                        "Drug: Dupilumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Dupilumab",
                    "description": "dupilumab 600 mg injection initially and then 300 mg every other week",
                    "armGroupLabels": [
                        "dupilumab treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks",
                    "description": "Change in EASI score from baseline to 8-12 weeks. Scores range from 0 to 72, with higher scores indicating more severity.",
                    "timeFrame": "baseline and 8-12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. 18 years of age or older\n2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of \u22657\n\nExclusion Criteria:\n\n1. Known pregnancy\n2. Known immunodeficiencies\n3. Known parasitic infection -",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jeffrey Cheng, MD, PhD",
                    "role": "CONTACT",
                    "phone": "415 575 0524",
                    "email": "rashes@ucsf.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jeffrey Cheng, MD, PhD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Raymond Cho, MD, PhD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jeffrey Cheng, MD, PhD",
                            "role": "CONTACT",
                            "email": "rashes@ucsf.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003872",
                    "term": "Dermatitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7071",
                    "name": "Dermatitis, Atopic",
                    "relevance": "LOW"
                },
                {
                    "id": "M7067",
                    "name": "Dermatitis",
                    "asFound": "Dermatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7655",
                    "name": "Eczema",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}